Clinical Trial Update: Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a fatty acid synthase inhibitor for castration-resistant prostate cancer is currently recruiting. The sponsor is Wake Forest…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Prostate Cancer, Refractory Cancer | Phase 2 | Status: RECRUITING